HIGHLIGHTS OF PRESCRIBING INFORMATIONThese highlights do not include all the information needed to use TORISEL® safely and effectively. See full prescribing information for TORISEL. TORISEL Kit (temsirolimus) injection, for intravenous use Initial U.S. Approval: 2007 INDICATIONS AND USAGETORISEL® is a kinase inhibitor indicated for the treatment of advanced renal cell carcinoma. (1) DOSAGE AND ADMINISTRATION
DOSAGE FORMS AND STRENGTHSTORISEL injection, 25 mg/mL supplied with DILUENT for TORISEL. (3) CONTRAINDICATIONSTORISEL is contraindicated in patients with bilirubin > 1.5×ULN. (4) WARNINGS AND PRECAUTIONS
ADVERSE REACTIONSThe most common adverse reactions (incidence ≥30%) are rash, asthenia, mucositis, nausea, edema, and anorexia. The most common laboratory abnormalities (incidence ≥30%) are anemia, hyperglycemia, hyperlipidemia, hypertriglyceridemia, elevated alkaline phosphatase, elevated serum creatinine, lymphopenia, hypophosphatemia, thrombocytopenia, elevated AST, and leukopenia. (6)To report SUSPECTED ADVERSE REACTIONS, contact Wyeth Pharmaceuticals Inc. at 1-800-934-5556 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch DRUG INTERACTIONSUSE IN SPECIFIC POPULATIONSLactation: Do not breastfeed. (8.2) See 17 for PATIENT COUNSELING INFORMATION. Revised: 4/2023 |

If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.
TORISEL® Highlights (temsirolimus)
Resources
To report an adverse event related to a Pfizer product and you are not part of a clinical trial* for this product, click the link below to submit your information: Pfizer Safety Reporting Site
*If you are involved in a clinical trial for either product, adverse events should be reported to your coordinating study site.
If you cannot use the above website to report an adverse event related to a Pfizer product, please call Pfizer Medical Information at (800) 438-1985.
(800)-332-1088.